摘要
Background:The mortalities of hepatobiliary malignancies are high.With the failure of conventional chemotherapy and unsatisfactory outcome of molecular targeted drugs,immune-based therapy has become a new focus of research in hepatobiliary cancers treatment.Data sources:We performed a Pub Med search with relevant articles published up to May 2022 and the following keywords:cellular immunotherapy,hepatobiliary cancer,antigen receptor T cell therapy,and receptor-engineered T cell.Information of clinical trials was obtained from https://clinicaltrials.gov/.Results:Cell therapies for hepatobiliary malignancies are at early stage of development.The current review showed that cellular therapies are safe and feasible in patients.These findings provide an important platform for future lager scale clinical trials on immunotherapy in patients with hepatobiliary malignancies.Conclusions:With the continuous advances of cellular immunotherapy,the combination of cellular immunotherapy with surgery,chemotherapy and radiotherapy will be new therapeutic strategies for patients with hepatobiliary cancer.
基金
supported by grants from the International Science and Technology Cooperation Projects(2016YFE0107100)
the Capital Special Research Project for Health Development(2014-2-4012)
the Beijing Natural Science Foundation(L172055 and 7192158)
the National Ten-thousand Talent Program
the Fundamental Research Funds for the Central Universities(3332018032)
the CAMS Innovation Fund for Medical Science(CIFMS)(2017-I2M-4-003 and 2018-I2M-3-001)。
